Prosecution Insights
Last updated: August 16, 2026
Application No. 17/510,882

PEPTIDE-BASED VACCINE GENERATION

Final Rejection §103§112
Filed
Oct 26, 2021
Priority
Oct 27, 2020 — provisional 63/105,926
Examiner
BICKHAM, DAWN MARIE
Art Unit
1685
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
NEC Laboratories America Inc.
OA Round
4 (Final)
43%
Grant Probability
Moderate
5-6
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 43% of resolved cases
43%
Career Allowance Rate
15 granted / 35 resolved
-17.1% vs TC avg
Strong +66% interview lift
Without
With
+66.4%
Interview Lift
resolved cases with interview
Typical timeline
4y 4m
Avg Prosecution
35 currently pending
Career history
65
Total Applications
across all art units

Statute-Specific Performance

§101
33.3%
-6.7% vs TC avg
§103
24.4%
-15.6% vs TC avg
§102
11.5%
-28.5% vs TC avg
§112
23.0%
-17.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 35 resolved cases

Office Action

§103 §112
DETAILED ACTION Applicant’s response, filed 06/05/2026, has been fully considered. Rejections and/or objections not reiterated from previous Office Actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claim Status Claims 1, 3-12, and 14-20 are pending. Claims 2 and 13 are canceled. Claims 1, 3-12, and 14-20 are rejected. Priority The instant Application claims domestic benefit to US provisional application 63/105,926, filed 10/27/2020. Accordingly, each of claims 1, 3-12, and 14-20 are afforded the effective filing date of the 10/27/2020. Information Disclosure Statement The information disclosure statement (IDS) filed on 10/26/2021 is in compliance with the provisions of 37 CFR 1.97 and has therefore been considered. A signed copy of the IDS document is included with this Office Action. Drawings The Drawings submitted 09/24/2025 are accepted. Claim Rejections- 35 USC § 112 35 USC § 112(a) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. Claims 1, 3-12, and 14-20 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This rejection pertains to new matter. The rejection is newly stated based upon claim amendment. Claim 1 recites “a Kullback-Leibler (KL) -based mutual information decomposition term”. The specification as published provides support for a regularization term may be expressed as …where MI(·) is the mutual information [0033] and “The following pseudo-code may be optionally used to further disentangle the attribute representation a from the structural/sequence content representation s besides minimizing the KL-divergence based mutual information above” [0033]. However, there is not support within the specification, nor has Applicant provided such support, for a Kullback-Leibler (KL) -based mutual information decomposition term. There is no guidance that defines the metes and bounds of what this information decomposition term is. Without understanding or knowing the metes and bounds of this claim, it cannot be properly interpretated. Therefore, the limitation introduces new matter. Claims 3-12, and 14-20 are rejected based on their dependency from claim 1. Claim Rejections - 35 USC § 103 The outstanding 103 rejections to the claims are withdrawn in view of the amendments and applicants persuasive arguments that the prior art rejection does not teach iteratively training a neural network of the autoencoder model using a set of training peptide sequences, the training includes updating a variational decoder with a sample-based upper bound and a Kullback-Leibler (KL) -based mutual information decomposition term. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. A. Claim(s) 1, 4-5, 9-10, 12, 15-16, and 19-20 is/are rejected under 35 U.S.C. 103 as being unpatentable over Das et al. (Das, Payel, et al. "Pepcvae: Semi-supervised targeted design of antimicrobial peptide molecules." arXiv preprint arXiv:1810.07743 (2018), previously cited), Cheng et al. (Cheng, Pengyu, et al. "Improving disentangled text representation learning with information-theoretic guidance." arXiv preprint arXiv:2006.00693 (2020), previously cited) in view of Sidom et al. (Sidhom, John-William, et al. "DeepTCR: a deep learning framework for understanding T-cell receptor sequence signatures within complex T-cell repertoires." BioRxiv (2019), previously cited), in view of Zhang et al. (Zhang, Jianfu, et al. "Multi-attribute transfer via disentangled representation." Proceedings of the AAAI conference on artificial intelligence. Vol. 33. No. 01. 2019, newly cited), in further view of Sidom et al. (Sidhom, John-William, Drew M. Pardoll, and Alexander S. Baras. "Deep learning of the immune synapse." Cancer Research. Vol. 79, 2019, newly cited, henceforth referred to as Sidom2). Underlined text indicates newly recited portions necessitated by claim amendment. Claims 1 and 3-10 are directed to computer-implemented method. Das discloses PepCVAE: semi-supervised targeted design of antimicrobial peptide molecules[title]. Das further discloses the model architecture was implemented in PyTorch [p. 5, par. 3] which reads on a computer-implemented method. Claims 12 and 14-20 are directed to a system for generating a peptide sequence, comprising: a hardware processor; and a memory that stores a computer program product. Das discloses the model architecture was implemented in PyTorch [p. 5, par. 3] which reads on a computer-implemented method. Although Das does not implicitly disclose a system, it is implied that to use the architecture with PyTorch and an autoencoder, a processor and memory are required. Claims 1 and 12 are directed to …of generating a peptide sequence, comprising: Das discloses a peptide generation framework PepCVAE, based on a semi-supervised variational autoencoder (VAE) model, for designing novel antimicrobial peptide (AMP) sequences [abstract]. iteratively training a neural network of the autoencoder model using a set of training peptide sequences, the training includes updating a variational decoder with a sample-based upper bound and a Kullback-Leibler (KL) -based mutual information decomposition term Das discloses we pretrain the VAE for 20k iterations (_ 7 epochs) followed by 5k iterations (34 epochs) of full model training [p. 5, par. 3]. Das is silent on the training includes updating a variational decoder with a sample-based upper bound and a Kullback-Leibler (KL) -based mutual information decomposition term. However, Cheng discloses improving disentangled text representation learning with information-theoretic guidance [title]. Cheng further discloses maximizing I(c; x) to ensure that the content embedding s sufficiently encapsulates information from the sentence x [p. 7532, col. 1, par. 3]. Cheng further discloses the embedding s is expected to contain rich style information. Therefore, the mutual information I(s; y) should be maximized [p. 7532, col. 1, par. 3]. Cheng also discloses to estimate I(s; c), we propose a novel sample based upper bound [p. 7533, col. 1, par. 2]. Cheng further discloses they assume we have M latent embedding pairs… drawn from p(s; c) and they derive an upper bound of mutual information based on the samples [p. 7533, col. 1, par. 2]. Cheng also discloses a prior distribution p(s; c) = p(s)p(c), as the product of two multivariate unit variance Gaussians, is used to regularize the posterior distribution q_(s; cjx) by KL-divergence minimization [p. 7533, col. 2, par. 5]. Cheng further discloses the log-likelihood term for text reconstruction should be maximized [p. 7533, col. 2, par. 5]. transforming an input peptide sequence that has been identified as binding to a major histocompatibility complex (MHC) into disentangled representations, including a structural representation and an attribute representation, using an autoencoder model; Das discloses during training, known peptide sequences are fed into the encoder, which generates their respective latent codes and then the latent code is later decoded into a peptide sequence using the decoder [p. 3, fig. 1]. Das further discloses in order to perform controllable generation approach augments the unstructured latent codes ~z with a set of structured variables c, which are trained to control a salient and independent attribute of the sequence: whether it is antimicrobial, toxic, soluble, etc. [p. 4, par. 2], but is silent on major histocompatibility complex (MHC). However, Sidom discloses DeepTCR: a deep learning framework for understanding Tcell receptor sequence signatures within complex T-cell repertoires [title]. Sidom further discloses the implementation of a variational autoencoder (Fig. 1a) starts by taking a TCR sequence and following featurization as described previously, is transformed into a latent space that is parametrized by a multidimensional unit Gaussian distribution [p. 6, par. 1], which reads on transforming an input peptide sequence that has been identified as binding to a major histocompatibility complex (MHC) into disentangled representations. modifying one of the disentangled representations; Neither Das or Sidom discloses modifying one of the disentangled representations. However, Zhang discloses multi-attribute transfer via disentangled representation [title]. Zhang further discloses a model that learns disentangled representations for multiple different attributes, implementing a function that user can select some specific attributes and swap the corresponding parts of embeddings to “swap” the attributes, or apply embedding interpolation to manipulate different attributes [p. 9196, col. 1, par. 4]. Zhang also discloses implement our model using an auto-encoder, training on labeled input data pairs by swapping designated parts of embeddings [p. 9196, col. 1, par. 1]. Zhang further discloses the disentanglement of hidden units assures that only the specified attributes are changed while the others remain intact [p. 9201, col. 2, par. 3], which reads on modifying an attribute. transforming the disentangled representations, including the modified disentangled representation, to generate a new peptide sequence using the autoencoder model; and Das discloses as PepCVAE generates novel AMP sequences with higher long-range diversity, while being closer to the training distribution of biological peptides [abstract]. generating a peptide vaccine using the new peptide sequence. Das, Sidom, and Zhang are silent on generating a peptide vaccine. However, Sidom2 discloses deep learning algorithms have been utilized to achieve excellent performance in pattern-recognition tasks, such as in image and vocal recognition [DeepTCR]. Sidom2 further discloses the ability to learn complex patterns in data has tremendous implications in the genomics world, where sequence motifs become learned ‘features’ that can be used to predict functionality, guiding our understanding of disease and basic biology [DeepTCR]. Sidom2 also discloses accurately predicting and modeling these interactions in immune-oncology range from improved and potent vaccine design to biomarkers for predicting response to immunotherapy to furthering our understanding of immune recognition [abstract]. It would be obvious to generated those predicted peptide vaccines. Claims 3 and 14 are directed to wherein training the neural network of the autoencoder model includes minimizing loss function that includes a mutual information between the structural representation and the attribute representation and further includes a Wasserstein distance between sample of a posterior distribution and a Gaussian distribution. Das discloses minimize the loss with respect to the parameters and the classifier loss requires both real and generated sequences’ c attribute to be classified correctly, while minimizing the entropy H of the classifier encourages it to have high confidence in its predictions on generated data [p. 4, par. 2]. Sidom discloses to make inter-repertoire comparisons we measure the distance between these proportionality vectors using variety of distance metrics including Euclidean, Correlation, a symmetric KL-divergence, JS-divergence, and Wasserstein distance [p. 8, par. 1], which reads on a loss function. Das is silent on a Wasserstein distance between sample of a posterior distribution and a Gaussian distribution. However, Cheng further discloses IDEL reduces the dependency between style and content embeddings by minimizing a sample-based mutual information upper bound [p. 2, col. 1, par. 1]. Cheng also discloses a prior distribution p(s; c) = p(s)p(c), as the product of two multivariate unit variance Gaussians, is used to regularize the posterior distribution [p. 4, col. 2, par. 5]. Claims 4 and 15 are directed to wherein modifying the disentangled representations includes modifying an attribute representation of binding affinity. Das discloses in order to perform controllable generation approach augments the unstructured latent codes ~z with a set of structured variables c, which are trained to control a salient and independent attribute of the sequence: whether it is antimicrobial, toxic, soluble, etc. [p. 4, par. 2]. Das is silent on binding affinity. Sidom discloses 57,229 unique α/β pairs were collected with a count based measurement (as a proxy for binding affinity) to 44 specific peptide-MHC (pMHC) multimers and 6 negative controls [p. 29, fig 2] which reads on a binding affinity. Claims 5 and 16 is directed to wherein the binding affinity is a binding affinity between a peptide and the MHC. Das is silent on binding affinity. However, Sidom discloses 57,229 unique α/β pairs were collected with a count based measurement (as a proxy for binding affinity) to 44 specific peptide-MHC (pMHC) multimers and 6 negative controls [p. 29, fig 2] which reads on binding affinity between a peptide and a major histocompatibility complex. Claims 9 and 19 are directed to wherein modifying the disentangled representations includes changing coordinates of a vector representation of the disentangled representations within an embedding space. Neither Das or Sidom discloses modifying one of the disentangled representations. However, Zhang discloses multi-attribute transfer via disentangled representation [title]. Zhang further discloses a model that learns disentangled representations for multiple different attributes, implementing a function that user can select some specific attributes and swap the corresponding parts of embeddings to “swap” the attributes, or apply embedding interpolation to manipulate different attributes [p. 9196, col. 1, par. 4]. Zhang also discloses implement our model using an auto-encoder, training on labeled input data pairs by swapping designated parts of embeddings [p. 9196, col. 1, par. 1]. Zhang further discloses the disentanglement of hidden units assures that only the specified attributes are changed while the others remain intact [p. 9201, col. 2, par. 3], which reads on modifying an attribute. Claims 10 and 20 are directed to wherein transforming the input peptide sequence is performed using an encoder of the autoencoder model and transforming the disentangled representations is performed using a decoder of the autoencoder model. Das discloses known peptide sequences are fed into the encoder, which generates their respective latent codes and latent code is later decoded into a peptide sequence using the decoder [p. 3, par. 3]. In regards to claim(s) 1, 4-5, 9-10, 12, 15-16, and 19-20, it would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to combine Das with Sidom as they disclose methods for using VAE for peptide representation. The motivation would have been to define the attributes mentioned in Das with the specific attributes of peptide binding of Sidom to create a downstream pipeline with this improved featurization to make inter-repertoire comparisons as discloses by Sidom [abstract], a finding that one of ordinary skill in the art would have recognized that the results of the combination were predictable. In regards to claim(s) 1, 4-5, 9-10, 12, 15-16, and 19-20, it would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to combine Das and Sidom with Zhang as they disclose methods for using VAE disentangled representation. The motivation would have been to include the ability to modify attributes of Das and Sidom with the methods of Zhang to synthesize highly realistic sequences and alter the attribute labels for the sequences as disclosed by Zhang [abstract], a finding that one of ordinary skill in the art would have recognized that the results of the combination were predictable. In regards to claim(s) 1, 4-5, 9-10, 12, 15-16, and 19-20, it would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to combine Das, Sidom, and Zhang with Sidom2 as they disclose methods for using VAE disentangled representation. The motivation would have been to include the vaccine generation of Sidom2 with the methods of Das, Sidom, and Zhang for improved and potent vaccine design as disclosed by Sidom2[abstract], a finding that one of ordinary skill in the art would have recognized that the results of the combination were predictable. In regards to claim(s) 3 and 14, it would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to combine Das and Sidom with Cheng as they both disclose methods to transform data into disentangled representations. Cheng discloses improving disentangled text representation learning with information-theoretic guidance[title]. Cheng further discloses unsupervised representation learning and generation of text from a continuous space is an important topic in natural language processing [p. 1, par. 1]. The motivation would have been to modify the method of Das to be to include reducing the dependency between style and content embeddings by minimizing a sample-based mutual information upper bound to help reduce the dependence between embedding spaces as disclosed by Cheng [p. 9, col. 1, par. 1], a finding that one of ordinary skill in the art would have recognized that the results of the combination were predictable. B. Claim(s) 11 is/are rejected under 35 U.S.C. 103 as being unpatentable over Das et al. (Das, Payel, et al. "Pepcvae: Semi-supervised targeted design of antimicrobial peptide molecules." arXiv preprint arXiv:1810.07743 (2018), previously cited) in view of Sidom et al. (Sidhom, John-William, et al. "DeepTCR: a deep learning framework for understanding T-cell receptor sequence signatures within complex T-cell repertoires." BioRxiv (2019), previously cited), in view of Zhang et al. (Zhang, Jianfu, et al. "Multi-attribute transfer via disentangled representation." Proceedings of the AAAI conference on artificial intelligence. Vol. 33. No. 01. 2019, newly cited), in view of Sidom et al. (Sidhom, John-William, Drew M. Pardoll, and Alexander S. Baras. "Deep learning of the immune synapse." Cancer Research. Vol. 79, 2019, newly cited, henceforth referred to as Sidom2), and in further view of Rubenstein et al. (Rubenstein, Paul K., Bernhard Schölkopf, and Ilya Tolstikhin. "Learning disentangled representations with wasserstein auto-encoders." (2018), newly cited). Claim 11 is directed a computer-implemented method of generating a peptide sequence, comprising: training a Wasserstein neural network model using a set of training peptide sequences by minimizing a mutual information between a structural representation and an attribute representation of the training peptide sequences; transforming an input peptide sequence that has been identified as binding to a major histocompatibility complex (MHC) into disentangled structural and attribute representations, using an encoder of the Wasserstein neural network model; modifying one of the disentangled representations to alter an attribute to improve vaccine efficacy against a predetermined pathogen, including changing coordinates of a vector representation of the disentangled representations within an embedding space; and transforming the disentangled representations, including the modified disentangled representation, to generate a new peptide sequence using a decoder of the Wasserstein neural network model; and generating a peptide vaccine using the new peptide sequence. Claim 11 is similar to claims 1-3 and 8-9 as it is a computer implemented method of analyzing peptide sequences. However, more specifically claim 11 requires a Wasserstein neural network where claim 1 requires a general autoencoder model. Das, Sidom, Zhang, and Sidom2 are silent on a Wasserstein neural network. However, Rubenstein discloses learning disentangled representations with Wasserstein auto-encoders [title]. Rubenstein further discloses Wasserstein auto-encoders (WAEs) are a recently introduced auto-encoder architecture similarly to Variational auto-encoders (VAEs), WAEs describe a particular way to train probabilistic latent variable models (LVMs) [p. 1, par. 1]. Rubenstein also discloses LVMs act by first sampling a code (feature) vector Z from a prior distribution defined over the latent space and then mapping it to a random input point using a conditional distribution also known as the decoder [p. 1, par. 1]. In regards to claim(s) 11, it would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to combine Das with Rubenstein as they both are directed to learning disentangled representations. The motivation would have been to substitute the WAE of Rubenstein for the VAE of Das as WAE shares many of the properties of VAEs (stable training, encoder-decoder architecture, nice latent manifold structure). The goal, is to learn representations of datasets such that individual coordinates in the feature space correspond to human-interpretable generative factors (also referred to as factors of variation in the literature) and that learning such representations is essential for significant progress in machine learning research as disclosed by Rubenstein [p. 1, par. 5]. C. Claims 6-8, 17-18 are rejected under 35 U.S.C. 103 as being unpatentable over Das in view of Sidom, Zhang, and Sidom2, as applied to claims 1 and 12 as above, and in further view of Patronov et al. (Patronov, Atanas, and Irini Doytchinova. "T-cell epitope vaccine design by immunoinformatics." Open biology 3.1 (2013): 120139, newly cited). Claim 6 is directed to wherein modifying the disentangled representations includes modifying an attribute representation of antigen processing score. Das discloses in order to perform controllable generation approach augments the unstructured latent codes ~z with a set of structured variables c, which are trained to control a salient and independent attribute of the sequence: whether it is antimicrobial, toxic, soluble, etc. [p. 4, par. 2] which read on attribute representations. Das, Sidom, Zhang and Sidom2 are silent on an antigen processing score. However, Patronov discloses T-cell epitope vaccine design by immunoinformatics [title]. Patronov further discloses the improved knowledge of antigen recognition at molecular level has contributed to the development of rationally designed peptide vaccines [p. 2, col. 2, par. 4]. Patronov discloses a method to integrate the prediction of peptide MHC class I binding, proteaso mal C-terminal cleavage and transporter associated with antigen processing (TAP) transport efficiency [p. 5, col. 1, par. 3]. When one assesses the protein structure, the skilled artisan would readily evaluate the relevant properties such as binding affinity, t-cell receptor interactions, and antigen processing as disclosed by Patronov. Claims 7 and 17 are directed to wherein modifying the disentangled representations includes modifying an attribute representation of T-cell receptor interaction score. Das discloses in order to perform controllable generation approach augments the unstructured latent codes ~z with a set of structured variables c, which are trained to control a salient and independent attribute of the sequence: whether it is antimicrobial, toxic, soluble, etc. [p. 4, par. 2] which read on attribute representations. Das, Sidom, Zhang and Sidom2 are silent on an aT-cell receptor interaction score. However, Patronov discloses T-cell epitope vaccine design by immunoinformatics [title]. Patronov further discloses the improved knowledge of antigen recognition at molecular level has contributed to the development of rationally designed peptide vaccines [p. 2, col. 2, par. 4]. Patronov also discloses that the interaction between the T-cell receptor and the MHC–ligand complex were also studied via docking [p. 7, col. 2, par. 2]. When one assesses the protein structure, the skilled artisan would readily evaluate the relevant properties such as binding affinity, t-cell receptor interactions, and antigen processing as disclosed by Patronov. Claims 8 and 18 are directed to wherein modifying the disentangled representations includes altering an attribute to improve vaccine efficacy against a predetermined pathogen. Das discloses in order to perform controllable generation approach augments the unstructured latent codes ~z with a set of structured variables c, which are trained to control a salient and independent attribute of the sequence: whether it is antimicrobial, toxic, soluble, etc. [p. 4, par. 2] which read on attribute representations. Das, Sidom, Zhang and Sidom2 are silent on an aT-cell receptor interaction score. However, Patronov discloses T-cell epitope vaccine design by immunoinformatics [title]. Patronov further discloses the improved knowledge of antigen recognition at molecular level has contributed to the development of rationally designed peptide vaccines [p. 2, col. 2, par. 4]. Patronov also discloses that the interaction between the T-cell receptor and the MHC–ligand complex were also studied via docking [p. 7, col. 2, par. 2]. Patronov further discloses a method to integrate the prediction of peptide MHC class I binding, proteaso mal C-terminal cleavage and transporter associated with antigen processing (TAP) transport efficiency [p. 5, col. 1, par. 3]. Patronov also discloses the methodology of analyzing the pathogen genome to identify potential antigenic proteins is known as ‘reverse vaccinology’ [p. 3, col. 2, par. 2], which reads on a known pathogen. As relevant properties such as binding affinity, t-cell receptor interactions, and antigen processing all contribute to a vaccine efficacy, they would also affect the efficiency of said vaccine as disclosed by Patronov. In regards to claim(s) 6-8, 13, and 17-18, it would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to combine Das, Sidom, Zhang, and Sidom2 with Patronov as the method of Das and Sidom are directed to treatment by peptide sequence design. The motivation would have been to add the step of generating a vaccine of Zhang based on the new peptide sequence of Das and Sidom as the improved knowledge of antigen recognition at molecular level has contributed to the development of rationally designed peptide vaccines as disclosed by Zhang [p.2, col. 2, par. 4], a finding that one of ordinary skill in the art would have recognized that the results of the combination were predictable. Conclusion No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Inquiries Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dawn Bickham whose telephone number (703)756-1817. The examiner can normally be reached on Monday - Friday 8-4. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Olivia Wise can be reached on (571)272-2249. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see https://ppair-my.uspto.gov/pair/PrivatePair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /D.M.B./Examiner, Art Unit 1685 /Soren Harward/Primary Examiner, TC 1600
Read full office action

Prosecution Timeline

Show 6 earlier events
Jan 14, 2026
Interview Requested
Jan 27, 2026
Request for Continued Examination
Jan 28, 2026
Response after Non-Final Action
Mar 09, 2026
Non-Final Rejection mailed — §103, §112
May 22, 2026
Interview Requested
May 28, 2026
Examiner Interview Summary
Jun 05, 2026
Response Filed
Jul 22, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12680137
METHOD OF PREDICTING FOR BENEFIT FROM IMMUNE CHECKPOINT INHIBITION THERAPY
5y 0m to grant Granted Jul 14, 2026
Patent 12637692
MACHINE LEARNING ACCELERATED PROTEIN ENGINEERING THROUGH FITNESS PREDICTION
5y 0m to grant Granted May 26, 2026
Patent 12637714
METHODS, AND SYSTEMS TO DETECT TRANSPLANT REJECTION
5y 3m to grant Granted May 26, 2026
Patent 12626819
MACHINE LEARNING MODELS FOR DETECTING OUTLIERS AND ERRONEOUS SENSOR USE CONDITIONS AND CORRECTING, BLANKING, OR TERMINATING GLUCOSE SENSORS
5y 3m to grant Granted May 12, 2026
Patent 12620454
BAMBAM: PARALLEL COMPARATIVE ANALYSIS OF HIGH-THROUGHPUT SEQUENCING DATA
4y 8m to grant Granted May 05, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
43%
Grant Probability
99%
With Interview (+66.4%)
4y 4m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 35 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month